Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 160,544 shares, a decrease of 68.6% from the February 26th total of 510,812 shares. Based on an average daily volume of 845,133 shares, the short-interest ratio is currently 0.2 days. Currently, 6.3% of the company’s stock are short sold. Currently, 6.3% of the company’s stock are short sold. Based on an average daily volume of 845,133 shares, the short-interest ratio is currently 0.2 days.

Cardio Diagnostics Stock Down 4.9%

Shares of NASDAQ CDIO opened at $2.14 on Wednesday. The stock’s 50 day moving average price is $2.67 and its two-hundred day moving average price is $3.25. Cardio Diagnostics has a 52-week low of $0.97 and a 52-week high of $17.39. The stock has a market capitalization of $6.33 million, a P/E ratio of -0.58 and a beta of 2.28.

Cardio Diagnostics (NASDAQ:CDIO) last issued its earnings results on Friday, March 13th. The company reported ($0.80) EPS for the quarter. Cardio Diagnostics had a negative return on equity of 71.75% and a negative net margin of 40,612.50%. On average, analysts anticipate that Cardio Diagnostics will post -0.55 EPS for the current year.

Wall Street Analysts Forecast Growth

CDIO has been the subject of a number of analyst reports. Wall Street Zen upgraded Cardio Diagnostics to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardio Diagnostics in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Institutional Trading of Cardio Diagnostics

A hedge fund recently raised its stake in Cardio Diagnostics stock. DRW Securities LLC grew its holdings in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,463 shares of the company’s stock after purchasing an additional 22,298 shares during the period. DRW Securities LLC owned 2.21% of Cardio Diagnostics worth $110,000 as of its most recent SEC filing. Institutional investors own 8.06% of the company’s stock.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.